Abstract | BACKGROUND: It is unclear whether selective infarct-related artery (sIRA) administration of glycoprotein IIb/IIIa receptor inhibitors (GPI) may further improve myocardial reperfusion without increasing bleeding in patients with ST-elevation myocardial infarction ( STEMI). The aim of this study was to compare the impacts of sIRA infusion with conventional intracoronary (IC) administration of GPI tirofiban on myocardial reperfusion and clinical prognosis in STEMI patients. METHODS: RESULTS: Similar primary endpoints ( CTFC of 28 ± 17 vs 27 ± 15; P=.841) were observed in the sIRA and conventional IC administration groups, respectively. The incidence of major adverse cardiac events (6.5% vs 5.2% at 30 days [P=.688] and 8.4% vs 7.3% at 6 months [P=.762]) and in-hospital major or minor bleeding (9.3% vs 8.3%; P=.800) were comparable in both groups. CONCLUSIONS: After thrombus aspiration, sIRA infusion of tirofiban does not improve myocardial reperfusion assessed by CTFC, as well as ischemic or bleeding events in this study.
|
Authors | Yi Chen, Peng Zhou, Hongbing Yan, Hanjun Zhao, Li Song, Chen Liu, Bo Zhao, Yunpeng Chi, Shaoping Wang, Jian Wang |
Journal | The Journal of invasive cardiology
(J Invasive Cardiol)
Vol. 25
Issue 8
Pg. 376-82
(Aug 2013)
ISSN: 1557-2501 [Electronic] United States |
PMID | 23913601
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Tyrosine
- Tirofiban
|
Topics |
- Aged
- Cardiac Catheterization
(methods)
- Electrocardiography
- Female
- Follow-Up Studies
- Hemorrhage
(epidemiology)
- Humans
- Infusions, Intra-Arterial
- Male
- Middle Aged
- Myocardial Infarction
(physiopathology, therapy)
- Myocardial Reperfusion
(methods)
- Percutaneous Coronary Intervention
(methods)
- Platelet Aggregation Inhibitors
(administration & dosage, therapeutic use)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Prevalence
- Prospective Studies
- Risk Factors
- Tirofiban
- Treatment Outcome
- Tyrosine
(administration & dosage, analogs & derivatives, therapeutic use)
|